User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

7077

Interactions with Platform & by Email *

INTERACTIONS

991

Unique # Participated *

PARTICIPANTS

212

Responses Validated *

VALIDATIONS

40

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability And Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions And Scope Of Study.....I-3
Cytotoxic Therapies.....I-3
Targeted Therapies.....I-3
  
   A Curtain Raiser.....II-1
Table 1: New Cases of Colorectal Cancer Diagnosed in the US for 2003-2006 (includes corresponding Graph/Chart).....II-1
1$350
   Table 2: Mortality Due to Colorectal Cancer in North America (2000-2003)-Breakdown by Region-United States, Canada and Mexico (includes corresponding Graph/Chart).....II-2

Table 3: Mortality Due to Colorectal Cancer in Latin America (2000-2003)-Breakdown by Region-Brazil, Argentina, Venezuela, Peru, and Chile (includes corresponding Graph/Chart).....II-2
1$350
   Table 4: Mortality Due to Colorectal Cancer in Asia-Pacific (2000-2003)-Breakdown by Region-China, Japan, India, Indonesia, Philippines, Australia, Thailand, South Korea, Malaysia, Hong Kong, New Zealand, Singapore and Taiwan (includes corresponding Graph/Chart).....II-3

Table 5: Mortality Due to Colorectal Cancer in Western Europe (2000-2003)-Breakdown by Region-Belgium, Austria, Denmark and Finland (includes corresponding Graph/Chart).....II-3
1$350
   Table 6: Staged Incidence of Cancer in the US by Race/Ethnicity: (1992-2000) (includes corresponding Graph/Chart).....II-4
Why Screening Rate is Low in Colorectal Cancer?.....II-4
1$350
   Strategies to Increase Screening Rate.....II-5
Early Screening & Detection- A Antidotes to Beat the Odds.....II-5
Test at Home.....II-5
1$100
   Breakdown of Colorectal Cancer Cases Based on the Risk Category.....II-6
Guidelines for Screening & Surveillance For Early Detection of Colorectal
  Cancer.....II-6
1$100
   Who is at a Greater Risk of Developing Colorectal Cancer?.....II-7
Genetic Disposition.....II-7
Table 7: Selected Risk Factors and their Relative Risk Percentage in Colorectal Cancer (includes corresponding Graph/Chart).....II-7
1$350
   Happy Days are Here Again.....II-8
Table 8: Five Year Disease -Free Survival Rate of Various Cancers by Type- Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, and Malignant Melanoma (includes corresponding Graph/Chart).....II-8
1$350
   An Insight into Colorectal Cancer Therapeutic Alternatives.....II-9
1$100
   Is Huge Cost of Drugs a Major Concern?.....II-10
Price Comparisons Among Leading Cancer Drugs Currently Available.....II-10
Is Cytotoxic Therapy Heading Towards the Sunset?.....II-10
1$100
   An Insight into Cytotoxic Drugs Available in the US Colorectal Cancer Market.....II-11
Expiry Period of Leading Cytotoxic Drugs- Camptosar, Eloxatin, and Xeloda.....II-11
5-FU Struggling to Hold Share.....II-11
Xeloda on a Rise with Growing Indications.....II-11
1$100
   Ongoing Phase III Clinical Trials to Evaluate Efficacy of Xeloda in Colorectal
  Cancer.....II-12
Edotecarin-An Evolving Cytotoxic Therapy.....II-12
Targeted Therapies-All Set to Stake a Claim Over the Future .....II-12
1$100
   Avastin- The Wonder Drug.....II-13
Table 9: Key Parameters that Promote use of Avastin (includes corresponding Graph/Chart).....II-13
PTK787 (vatalanib).....II-13
1$350
   ABX-EGF.....II-14
Targeted Therapies Add Value to Treatment Strategies.....II-14
Panitumumab- A Key Contender to Erbitux.....II-14
1$100
   PTK787 v/s Avastin- Serious Warfare.....II-15
Combination Therapy- Offering a Lucrative Option.....II-15
A Peek into Standard Combination Therapies in Colorectal Cancer and their
  Status.....II-15
1$100
   Reoccurrence of Cancer –A Prime Concern.....II-16
Table 10: Revenues from Adjuvant Colorectal Cancer Therapies in the US 2004-2007 (In US$ Million) (includes corresponding Graph/Chart).....II-16

Table 11: Number of Colorectal Cancer Patients in Adjuvant Settings in the US: 2001-2007 (includes corresponding Graph/Chart).....II-16
1$350
   Adjuvant Therapy in Colon Cancer.....II-17
Adjuvant Therapy in Rectal Cancer.....II-17
Colorectal Cancer Drugs in Adjuvant Settings.....II-17
1$100
   Prominent Products Still in Pipeline.....II-18
A Snapshot of Potential Drugs in the Pipeline.....II-18
2$200
   Adapalene (CD271) Retinoid Agent Induces Apoptosis in Colon Cancer Cells.....II-20
Laparoscopic Surgery Vs Open Surgery.....II-20
Discontinuation of Chemotherapy Drugs Raises the Chances of Reoccurrence.....II-20
Colorectal Cancer and Natural Substances.....II-20
Magnesium.....II-20
1$100
   Vitamin D Protects Development of Tumor in Colon.....II-21
High Intake of Vitamin B Reduces Risk in Women.....II-21
Diet Rich in Flavonoids Fights Well Against Colorectal Cancer.....II-21
Colorectal Cancer and Other Medications.....II-21
NSAIDs Reduce the Risk of Colorectal Cancer.....II-21
Efficacy of Cancer Vaccine, ALVAC-CEA/B7.1, in Colorectal Cancer.....II-21
1$100
   Insulin Therapy in type 2 Diabetic Patients Increases Risk.....II-22
1$100
   Colorectal Cancer-An Insight.....II-23
Colorectal Cancer . What is it .!!!.....II-23
What are the Symptoms?.....II-23
1$100
   Risk Factors.....II-24
Selected General Risk Factors and their Relative Risk Rate in Colorectal
  Cancer.....II-24
1$100
   Screening and Treatment.....II-25
Screening Options.....II-25
Digital Rectal Examination (DRE).....II-25
Fecal Occult Blood Test.....II-25
Flexible Sigmoidoscopy.....II-25
Barium Enema.....II-25
Colonoscopy.....II-25
Additional Screening Options Of Recent Origin.....II-25
DNA-based Stool Test.....II-25
1$100
   Virtual Colonoscopy.....II-26
A Comparative Analysis of Various Colorectal Cancer Screening Options Based on
  Parameters Such as Complexity, Risk Element, Potential Effectiveness,
    Overall Performance and Significant Limitations.....II-26
Appropriate Time Frame for Screening and Surveillance of Colorectal Cancer for
  Both Women and Men in the Age Group of 50 or More.....II-26
1$100
   Supportive Diagnostic Tests.....II-27
Diagnosis/Treatment Options.....II-27
Partial Colectomy.....II-27
Chemotherapy.....II-27
Surgery.....II-27
Radiation Therapy.....II-27
1$100
   A Structural Analysis of Available Treatment Options in Colorectal Cancer.....II-28
Staging.....II-28
1$100
   Colorectal Cancer Therapies-At a Glance.....II-29
Cytotoxic Therapies.....II-29
5-FU (Fluorouracil).....II-29
Camptosar (Irinotecan).....II-29
Eloxatin (Oxaliplatin).....II-29
1$100
   Xeloda (Capecitabine).....II-30
Targeted Therapies.....II-30
Angiogenesis Pathway.....II-30
1$100
   Avastin (bevacizumab).....II-31
EGF Pathway.....II-31
Erbitux (cetuximab).....II-31
1$100
   Cell Proliferation/Apoptosis.....II-32
Immune Response.....II-32
Cancer Vaccines.....II-32
Monoclonal Antibodies & their Function.....II-32
1$100
   An Insight into the Targeted Therapies.....II-33
A Synoptic Review of Available Drugs Indicated in Treating Colorectal
  Cancer.....II-33
1$100
   Chugai Applies for Quick Approval of Avastin in Japan.....II-34
Genentech Obtains FDA Approval for Avastin in Combination Therapy.....II-34
US FDA Approves Adjuvant Status for Roche’s Oral Xeloda.....II-34
1$100
   Antisoma’s AS 1404 and Avastin Combination Therapy Proves Effective in Colon and Lung
  Cancer.....II-35
ImClone Systems and Bristol-Myers Squibb Receive Approval for Erbitux®
  Injection.....II-35
John Hopkins Develops Colorectal Cancer Blood Test Jointly with Howard Hughes Medical
  Institute and Indivumed.....II-35
Genentech Receives FDA Approval for Avastin.....II-35
1$100
   Oxford BioMedica Gains Approval for Phase II Trial of TroVax®.....II-36
Roche’s Xeloda Gets Clearance as First-Line Colorectal Cancer Treatment.....II-36
LabCorp Introduces DNA-based Colorectal Cancer Test.....II-36
1$100
   Amgen Acquires Abgenix.....II-37
Chiron Merges with Novartis.....II-37
Bayer to Acquire Schering AG.....II-37
Biosite Collaborates with Oxford Genome.....II-37
Medarex Collaborates with Oxford Genome Sciences.....II-37
1$100
   Pharmexa Acquires GemVax.....II-38
AstraZeneca to Acquire KuDOS Pharmaceuticals.....II-38
Aphton Corporation Acquires Igeneon.....II-38
IDM S.A. and Epimmune Merge to Form IDM Pharma.....II-38
Hybridon Renamed as Idera Pharmaceuticals.....II-38
Merck KGaA Acquires Rights for Taiho Pharmaceutical’s UFT.....II-38
Novartis and Schering Co-Promote PTK787/ZK 222584 Cancer Drug.....II-38
1$100
   TWTI and Genzyme Genetics Set Up a Marketing Association.....II-39
Callisto Receives Patent for its Colon Cancer Drug.....II-39
Amgen and Abgenix Receive FDA Approval for Panitumumab in Metastatic Colorectal
  Cancer.....II-39
ADVENTRX Receives MHRA Approval to Initiate Phase IIb Clinical Trial.....II-39
Sanofi Acquires Aventis to Form Sanofi-Aventis.....II-39
1$100
   Amgen Inc. (USA).....II-40
Bristol-Myers Squibb (USA).....II-40
F.Hoffmann-La Roche Ltd. (Switzerland).....II-40
Genentech, Inc. (USA).....II-40
1$100
   Imclone Systems Inc. (USA).....II-41
Novartis AG (Switzerland).....II-41
Oxford Biomedica (UK).....II-41
Pfizer Inc. (USA).....II-41
1$100
   Sanofi-Aventis (France).....II-42
Schering AG (Germany).....II-42
1$100
   Table 12: World Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region/Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-43

Table 13: World 10-Year Perspective for Colorectal Cancer Therapies by Geographic Region/Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010.....II-43
1$350
   Table 14: World Recent Past, Current & Future Analysis for Cytotoxic Therapies for Colorectal Cancer by Geographic Region/Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-44

Table 15: World 10-Year Perspective for Cytotoxic Therapies for Colorectal Cancer by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010 .....II-44
1$350
   Table 16: World Recent Past, Current & Future Analysis for Camptosar in Colorectal Cancer by Geographic Region/ Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-45

Table 17: World 10-Year Perspective for Camptosar in Colorectal Cancer by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010 .....II-45
1$350
   Table 18: World Recent Past, Current & Future Analysis for Eloxatin in Colorectal Cancer by Geographic Region/ Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-46

Table 19: World 10-Year Perspective for Eloxatin in Colorectal Cancer by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010.....II-46
1$350
   Table 20: World Recent Past, Current & Future Analysis for Xeloda in Colorectal Cancer by Geographic Region/Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding graph/chart).....II-47

Table 21: World 10-Year Perspective for Xeloda in Colorectal Cancer by Geographic Region/Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010.....II-47
1$350
   Table 22: World Recent Past, Current & Future Analysis for Targeted Therapies for Colorectal Cancer by Geographic Region/Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart).....II-48

Table 23: World 6-Year Perspective for Targeted Therapies for Colorectal Cancer by Geographic Region/Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010 .....II-48
1$350
   Table 24: World Recent Past, Current & Future Analysis for Avastin in Colorectal Cancer by Geographic Region/ Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart).....II-49

Table 25: World 6-Year Perspective for Avastin in Colorectal Cancer by Geographic Region/Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010 .....II-49
1$350
   Table 26: World Recent Past, Current & Future Analysis for Erbitux in Colorectal Cancer by Geographic Region/ Country – United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart).....II-50

Table 27: World 6-Year Perspective for Erbitux in Colorectal Cancer by Geographic Region/Country – Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010 .....II-50
1$350
   A. Market Analysis.....III-1
Introduction.....III-1
Market Accelerators.....III-1
Market Challenges.....III-1
Market Inhibitors.....III-1
Why Cost of Cancer Drugs is Too High in the US?.....III-1
1$75
   Free-market Healthcare System- “For” & “Against”.....III-2
Erbitux- Making a Way Through the Colorectal Cancer Market.....III-2
Erbitux-A Blockbuster Drug in Third-Line Therapy.....III-2
1$75
   Erbitux Enters the Genre of Second-Line Therapies.....III-3
Who Leads the Pack?.....III-3
Sanofi-Aventis- The Clear Leader.....III-3
Table 28: US Colorectal Cancer Market (2004): Percentage Breakdown of Leading Players-Sanofi-Aventis, Genentech, Pfizer, ImClone Systems/Bristol Myers-Squibb, Roche, and Generic Manufacturers-Ranked by Revenue (includes corresponding Graph/Chart).....III-3
1$200
   Table 29: US Colorectal Cancer Market for Cytotoxic Therapies (2004): Percentage Breakdown of Leading Players-Sanofi-Aventis, Pfizer, Roche and Generic Manufacturers-Ranked by Revenue (includes corresponding Graph/Chart).....III-4

Table 30: US Colorectal Cancer Market for Targeted Therapies (2004): Percentage Breakdown of Leading Players-Genentech and ImClone Systems/Bristol Myers-Squibb-Ranked by Revenues.....III-4
Crucial Statistics.....III-4
Table 31: Incidence of Colorectal Cancer in the US (2006)-Breakdown by Stages (includes corresponding Graph/Chart).....III-4

Table 32: US Colorectal Cancer Statistics for 2004 & 2003 (includes corresponding Graph/Chart).....III-4
1$200
   Table 33: New Cases of Colorectal Cancer in the US for the years 2005 & 2006-Breakdown by Cancer Type.....III-5

Table 34: New Colorectal Cancer Cases in the US in 2004 & 2003-Breakdown by Type & Gender .....III-5
Product Approvals/Launches.....III-5
2$400
   Strategic Developments.....III-71$75
   Focus on Select Players.....III-81$75
   B. Market Analytics.....III-9
Table 35: US Recent Past, Current & Future Analysis For Colorectal Cancer Therapeutics By Product Segments– Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda) And Targeted Therapies (Avastin And Erbitux) Markets Independently Analyzed With Annual Sales In Us$ Million For Years 2001 Through 2010 (includes corresponding Graph/Chart).....III-9
1$200
   Table 36: US 10-Year Perspective For Colorectal Cancer Therapeutics By Product Segments – Percentage Breakdown Of Dollar Sales For Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda) And Targeted Therapies (Avastin And Erbitux) For Years 2001, 2006 And 2010 (includes corresponding Graph/Chart).....III-10
1$200
   A. Market Analysis.....III-11
Focus on Select Countries.....III-11
Canada.....III-11
Incidence.....III-11
Vital Statistics.....III-11
Table 37: Canadian Cancer Market (2005): Percentage Breakdown of New Cancer Cases Among Men (includes corresponding Graph/Chart).....III-11

Table 38: Canadian Cancer Market (2005): Percentage Breakdown of Cancer Mortality Among Men (includes corresponding Graph/Chart).....III-11

Table 39: Canadian Cancer Market (2005): Percentage Breakdown of New Cancer Cases Among Women (includes corresponding Graph/Chart).....III-11
1$200
   Table 40: Canadian Cancer Market (2005): Percentage Breakdown of Cancer Mortality Among Women (includes corresponding Graph/Chart).....III-12

Table 41: New Colorectal Cancer Cases in Canada in 2005- By Gender.....III-12

Table 42: New Colorectal Cancer Cases in Canada in 2005–Breakdown By Age Group (includes corresponding Graph/Chart).....III-12

Table 43: Colorectal Cancer Mortality Statistics in Canada in 2005-Ranked By Gender.....III-12
1$200
   Table 44: Colorectal Cancer Mortality Statistics in Canada in 2005-Breakdown By Age Group (includes corresponding Graph/Chart).....III-13

Table 45: Incidence of Colorectal Cancer Among Men in Canada-By Region: 2005 (includes corresponding Graph/Chart).....III-13

Table 46: Incidence of Colorectal Cancer Among Women in Canada-By Region: 2005 (includes corresponding Graph/Chart).....III-13
1$200
   Finland.....III-14
Overview.....III-14
Active Screening Programs- A Mission to Fight Against Cancer.....III-14
Product Approvals.....III-14
1$75
   Strategic Developments.....III-152$150
   Focus on Select Players.....III-172$150
   B. Market Analytics.....III-19
Table 47: Rest of World Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Product Segments– Cytotoxic Therapies (Camptosar, Eloxatin and Xeloda) and Targeted Therapies (Avastin and Erbitux) Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-19

Table 48: Rest of World 10-Year Perspective for Colorectal Cancer Therapeutics by Product Segments – Percentage Breakdown of Dollar Sales for Cytotoxic Therapies (Camptosar, Eloxatin and Xeloda) and Targeted Therapies (Avastin and Erbitux) for Years 2001, 2006 and 2010 (includes corresponding Graph/Chart).....III-19
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com